Molecular targeting: PI3 kinase pathway.
Dancey
J E
JE
Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
D064413:3-Phosphoinositide-Dependent Protein Kinases; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis; D049109:Cell Proliferation; D002470:Cell Survival; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics* / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics* / Q000494:pharmacology*; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use
D064413:3-Phosphoinositide-Dependent Protein Kinases; D000903:Antibiotics, Antineoplastic; D019869:Phosphatidylinositol 3-Kinases; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D020123:Sirolimus